CABA — Cabaletta Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $245.48m
- $107.70m
Annual cashflow statement for Cabaletta Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -33.3 | -46.3 | -53 | -67.7 | -116 |
| Depreciation | |||||
| Non-Cash Items | 4.51 | 5.87 | 9.72 | 12.6 | 21.2 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.71 | 5.58 | -4.3 | 0.101 | 1.61 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -26.8 | -34.1 | -46.4 | -53.5 | -88.2 |
| Capital Expenditures | -0.635 | -1.17 | -2.45 | -0.687 | -2.21 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -7.35 | 7.17 | -24.8 | -21.8 | 49.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -7.98 | 6 | -27.2 | -22.5 | 47.3 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.024 | 48.9 | 33 | 188 | 11.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -34.8 | 20.8 | -40.6 | 112 | -29.3 |